JOHN PATRICK SHEEHAN

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa
    John P Sheehan
    Department of Medicine Hematology, University of Wisconsin Madison, 53706, USA
    Biochemistry 42:11316-25. 2003
  2. ncbi Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism
    John P Sheehan
    Department of Medicine Hematology, University of Wisconsin, Medical Sciences Center Rm 4285, 1300 University Avenue, Madison, WI 53706, USA
    Blood 107:3876-82. 2006
  3. ncbi The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin
    Qiu-Ping Yuan
    Department of Medicine/Hematology, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
    Biochemistry 44:3615-25. 2005
  4. ncbi The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X
    Tina M Misenheimer
    University of Wisconsin Madison, Department of Medicine Hematology Oncology, Madison, Wisconsin 53706, USA
    Biochemistry 46:7886-95. 2007
  5. ncbi Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite
    Yang Buyue
    Department of Medicine Hematology Oncology, University of Wisconsin Madison, Madison, WI 53706, USA
    Blood 114:3092-100. 2009
  6. ncbi The regulation of factor IXa by supersulfated low molecular weight heparin
    Tina M Misenheimer
    Department of Medicine Hematology Oncology, University of Wisconsin Madison, Madison, Wisconsin 53706, United States
    Biochemistry 49:9997-10005. 2010
  7. ncbi The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis
    Yang Buyue
    Departments of Medicine Hematology Oncology and Pathology, University of Wisconsin Madison, USA
    Blood 112:3234-41. 2008

Research Grants

  1. RESEARCH TRAINING IN HEMATOLOGY
    John Sheehan; Fiscal Year: 2007
  2. Physiologic and Pharmacologic Regulation of Factor IXa
    John Sheehan; Fiscal Year: 2009

Collaborators

Detail Information

Publications7

  1. ncbi Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa
    John P Sheehan
    Department of Medicine Hematology, University of Wisconsin Madison, 53706, USA
    Biochemistry 42:11316-25. 2003
    ..This exosite may contribute to the clinical efficacy of heparin and represents a novel target for antithrombotic therapy...
  2. ncbi Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism
    John P Sheehan
    Department of Medicine Hematology, University of Wisconsin, Medical Sciences Center Rm 4285, 1300 University Avenue, Madison, WI 53706, USA
    Blood 107:3876-82. 2006
    ..DHG also accelerated decay of the intact intrinsic tenase complex. Thus, DHG binds to an exosite on factor IXa that overlaps with the binding sites for LMWH and factor VIIIa, disrupting critical factor IXa-factor VIIIa interactions...
  3. ncbi The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin
    Qiu-Ping Yuan
    Department of Medicine/Hematology, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
    Biochemistry 44:3615-25. 2005
    ..Thus, LMWH inhibits intrinsic tenase by interacting with the heparin-binding exosite in the factor IXa protease domain, which disrupts interaction with the factor VIIIa A2 domain...
  4. ncbi The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X
    Tina M Misenheimer
    University of Wisconsin Madison, Department of Medicine Hematology Oncology, Madison, Wisconsin 53706, USA
    Biochemistry 46:7886-95. 2007
    ..These results suggest that the factor IXa heparin-binding exosite participates in both cofactor binding and protease activation, and cofactor affinity is linked to active site conformation and factor X interaction during enzyme assembly...
  5. ncbi Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite
    Yang Buyue
    Department of Medicine Hematology Oncology, University of Wisconsin Madison, Madison, WI 53706, USA
    Blood 114:3092-100. 2009
    ..Glycosaminoglycan-mediated intrinsic tenase inhibition is a novel antithrombotic mechanism with physiologic and therapeutic applications...
  6. ncbi The regulation of factor IXa by supersulfated low molecular weight heparin
    Tina M Misenheimer
    Department of Medicine Hematology Oncology, University of Wisconsin Madison, Madison, Wisconsin 53706, United States
    Biochemistry 49:9997-10005. 2010
    ..An extensive overlap exists between the heparin and factor VIIIa binding sites on the protease domain, with residues K126 and R233 dominating the heparin interaction and R165 dominating the cofactor interaction...
  7. ncbi The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis
    Yang Buyue
    Departments of Medicine Hematology Oncology and Pathology, University of Wisconsin Madison, USA
    Blood 112:3234-41. 2008
    ..7 minutes, 9.1 minutes (P </= .003), and more than 45 minutes. These data support the role of the factor IXa heparin-binding exosite as a critical regulator of coagulation and novel antithrombotic target...

Research Grants7

  1. RESEARCH TRAINING IN HEMATOLOGY
    John Sheehan; Fiscal Year: 2007
    ..The large pool of qualified candidates, excellent core facilities, institutional support, and broad range of scientific expertise fosters multidisciplinary approaches that will ensure successful careers in science for our trainees...
  2. Physiologic and Pharmacologic Regulation of Factor IXa
    John Sheehan; Fiscal Year: 2009
    ..Finally, these studies will provide proof of principle for this exosite as a critical therapeutic target, and identify lead compounds for a novel class of antithrombotics. ..